{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T22:06:40Z","timestamp":1763762800748,"version":"3.45.0"},"reference-count":19,"publisher":"The Pediatric Pharmacy Association","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10]]},"abstract":"\n OBJECTIVE<\/jats:title>\n \n People with cystic fibrosis (pwCF) have impaired bacterial mucociliary clearance, which can result in colonization with pathogens like\n Pseudomonas aeruginosa<\/jats:italic>\n and methicillin-resistant\n Staphylococcus aureus<\/jats:italic>\n (MRSA) in the lower airway. Although guidelines for the eradication of\n P. aeruginosa<\/jats:italic>\n in CF are well-established, MRSA eradication guidelines are lacking. This study aimed to determine the rates of MRSA eradication in pwCF based on a prescribed antibiotic regimen.\n <\/jats:p>\n <\/jats:sec>\n \n METHODS<\/jats:title>\n This retrospective chart review included pwCF with a first lifetime positive MRSA respiratory culture or first positive MRSA respiratory culture after at least 1 year of MRSA negativity (minimum of 4 negative respiratory cultures) obtained at Nationwide Children\u2019s Hospital between August 1, 2012, and February 28, 2022. Secondary outcomes assessed the impact of adding topical decontamination on MRSA eradication and the time to a subsequent MRSA-positive respiratory culture after completing the eradication regimen.<\/jats:p>\n <\/jats:sec>\n \n RESULTS<\/jats:title>\n Sixty-two patients were included, and 16% achieved MRSA eradication. Intravenous vancomycin transitioned to oral trimethoprim-sulfamethoxazole achieved the highest eradication rate of 75% (p = 0.008). Antibiotics consisting of dual therapy with rifampin and topical decontamination had a higher rate of eradication (25%) compared with antibiotics alone, antibiotics with topical decontamination, or no antibiotics. Four patients had no subsequent MRSA-positive cultures, including 2 patients who did not receive antibiotics.<\/jats:p>\n <\/jats:sec>\n \n CONCLUSIONS<\/jats:title>\n The transition from intravenous vancomycin to oral trimethoprim-sulfamethoxazole had the highest rate of MRSA eradication. Overall rates of MRSA eradication at 12 months in patients CF using antibiotics with or without topical decontamination are low.<\/jats:p>\n <\/jats:sec>","DOI":"10.5863\/jppt-24-00079","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T22:03:40Z","timestamp":1763762620000},"page":"601-606","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of Methicillin-Resistant Staphylococcus aureus Eradication in People With Cystic Fibrosis"],"prefix":"10.5863","volume":"30","author":[{"given":"Eva M.","family":"Byerley","sequence":"first","affiliation":[{"name":"Department of Pharmacy (EMB, KJN), Nationwide Children\u2019s Hospital, Columbus, OH"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vedat O","family":"Yildiz","sequence":"additional","affiliation":[{"name":"Biostatistics Resource at Nationwide Children\u2019s Hospital (VOY), Nationwide Children\u2019s Hospital, Columbus, OH"},{"name":"Center for Biostatistics, Department of Biomedical Informatics (VOY), The Ohio State University College of Medicine, Columbus, OH"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahid I.","family":"Sheikh","sequence":"additional","affiliation":[{"name":"Section of Pulmonary Medicine (SIS), Nationwide Children\u2019s Hospital, Columbus, OH"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly J.","family":"Novak","sequence":"additional","affiliation":[{"name":"Department of Pharmacy (EMB, KJN), Nationwide Children\u2019s Hospital, Columbus, OH"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3883","reference":[{"issue":"1","key":"i2331-348X-30-5-601-b01","series-title":"BMC Pulm Med","first-page":"174","article-title":"Cystic fibrosis lung environment and Pseudomonas aeruginosa infection","volume":"16","author":"Bhagirath","year":"2016","unstructured":"Bhagirath AY, Li Y, Somayajula D, Dadashi M, et al. Cystic fibrosis lung environment and Pseudomonas aeruginosa infection. BMC Pulm Med. 2016;16(1):174."},{"key":"i2331-348X-30-5-601-b02","article-title":"2022 Annual Data Report","year":"2023","unstructured":"Cystic Fibrosis Foundation Patient Registry. 2022 Annual Data Report. 2023. Accessed April 5, 2024. https:\/\/www.cff.org\/medical-professionals\/patient-registry."},{"issue":"2","key":"i2331-348X-30-5-601-b03","series-title":"Pediatr Pulmonol","first-page":"91","article-title":"Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis","volume":"34","author":"Emerson","year":"2002","unstructured":"Emerson J, Rosenfeld M, McNamara S, et al. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol. 2002;34(2):91\u2013100."},{"issue":"23","key":"i2331-348X-30-5-601-b04","series-title":"JAMA","first-page":"2386","article-title":"Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis","volume":"303","author":"Dasenbrook","year":"2010","unstructured":"Dasenbrook EC, Checkley W, Merlo CA, et al. Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis. JAMA. 2010;303(23):2386\u20132392."},{"issue":"10","key":"i2331-348X-30-5-601-b05","series-title":"Ann Am Thorac Soc","first-page":"1640","article-title":"Cystic fibrosis foundation pulmonary guideline. Pharmacologic approaches to prevention and eradication of initial Pseudomonas aeruginosa infection","volume":"11","author":"Mogayzel","year":"2014","unstructured":"Mogayzel PJ, Jr., Naureckas ET, Robinson KA, et al. Cystic fibrosis foundation pulmonary guideline. Pharmacologic approaches to prevention and eradication of initial Pseudomonas aeruginosa infection. Ann Am Thorac Soc. 2014;11(10):1640\u20131650."},{"issue":"Suppl 1","key":"i2331-348X-30-5-601-b06","series-title":"Infect Control Hosp Epidemiol","first-page":"S1","article-title":"Infection prevention and control guideline for cystic fibrosis: 2013 update","volume":"35","author":"Saiman","year":"2014","unstructured":"Saiman L, Siegel JD, LiPuma JJ, et al. Infection prevention and control guideline for cystic fibrosis: 2013 update. Infect Control Hosp Epidemiol. 2014;35 Suppl 1:S1\u2013S67."},{"key":"i2331-348X-30-5-601-b07","article-title":"Methicillin-resistant staphylococcus aureus (MRSA): report of the UK cystic fibrosis trust infection control working group","unstructured":"Cystic Fibrosis Trust. Methicillin-resistant staphylococcus aureus (MRSA): report of the UK cystic fibrosis trust infection control working group. Accessed June 3, 2023. https:\/\/www.cysticfibrosis.org.uk\/sites\/default\/files\/2020-12\/MRSA.pdf"},{"issue":"4","key":"i2331-348X-30-5-601-b08","series-title":"Thorax","first-page":"318","article-title":"Microbiological efficacy of early MRSA treatment in cystic fibrosis in a randomised controlled trial","volume":"72","author":"Muhlebach","year":"2017","unstructured":"Muhlebach MS, Beckett V, Popowitch E, et al. Microbiological efficacy of early MRSA treatment in cystic fibrosis in a randomised controlled trial. Thorax. 2017;72(4):318\u2013326."},{"issue":"9","key":"i2331-348X-30-5-601-b09","series-title":"Arch Pediatr Adolesc Med","first-page":"847","article-title":"Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis","volume":"165","author":"Treggiari","year":"2011","unstructured":"Treggiari MM, Retsch-Bogart G, Mayer-Hamblett N, et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Arch Pediatr Adolesc Med. 2011;165(9):847\u2013856."},{"issue":"4","key":"i2331-348X-30-5-601-b10","series-title":"Thorax","first-page":"286","article-title":"Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial","volume":"65","author":"Ratjen","year":"2010","unstructured":"Ratjen F, Munck A, Kho P, Angyalosi G. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Thorax. 2010;65(4):286\u2013291."},{"issue":"5","key":"i2331-348X-30-5-601-b11","series-title":"Clin Infect Dis","first-page":"707","article-title":"Impact of sustained eradication of new Pseudomonas aeruginosa infection on long-term outcomes in cystic fibrosis","volume":"61","author":"Mayer-Hamblett","year":"2015","unstructured":"Mayer-Hamblett N, Kloster M, Rosenfeld M, et al. Impact of sustained eradication of new Pseudomonas aeruginosa infection on long-term outcomes in cystic fibrosis. Clin Infect Dis. 2015;61(5):707\u2013715."},{"issue":"3","key":"i2331-348X-30-5-601-b12","series-title":"J Cyst Fibros","first-page":"357","article-title":"Eradication of persistent methicillin-resistant Staphylococcus aureus infection in cystic fibrosis","volume":"18","author":"Dezube","year":"2019","unstructured":"Dezube R, Jennings MT, Rykiel M, et al. Eradication of persistent methicillin-resistant Staphylococcus aureus infection in cystic fibrosis. J Cyst Fibros. 2019;18(3):357\u2013363."},{"issue":"1","key":"i2331-348X-30-5-601-b13","series-title":"BMC Pulm Med","first-page":"20","article-title":"Successful eradication of newly acquired MRSA in six of seven patients with cystic fibrosis applying a short-term local and systemic antibiotic scheme","volume":"18","author":"Kiefer","year":"2018","unstructured":"Kiefer A, Bogdan C, Melichar VO. Successful eradication of newly acquired MRSA in six of seven patients with cystic fibrosis applying a short-term local and systemic antibiotic scheme. BMC Pulm Med. 2018;18(1):20."},{"issue":"3","key":"i2331-348X-30-5-601-b14","series-title":"Pediatr Pulmonol","first-page":"654","article-title":"Outcomes of a methicillin-resistant Staphylococcus aureus (MRSA) eradication protocol in pediatric cystic fibrosis (CF) patients","volume":"55","author":"Belarski","year":"2020","unstructured":"Belarski E, Pettit R. Outcomes of a methicillin-resistant Staphylococcus aureus (MRSA) eradication protocol in pediatric cystic fibrosis (CF) patients. Pediatr Pulmonol. 2020;55(3):654\u2013659."},{"issue":"3","key":"i2331-348X-30-5-601-b15","series-title":"J Cyst Fibros","first-page":"478","article-title":"Drug-drug interactions with CFTR modulator therapy in cystic fibrosis: Focus on Trikafta\u00ae\/Kaftrio\u00ae","volume":"22","author":"Purkayastha","year":"2023","unstructured":"Purkayastha D, Agtarap K, Wong K, et al. Drug-drug interactions with CFTR modulator therapy in cystic fibrosis: Focus on Trikafta\u00ae\/Kaftrio\u00ae. J Cyst Fibros. 2023;22(3):478\u2013483."},{"issue":"4","key":"i2331-348X-30-5-601-b16","series-title":"ERJ Open Res","first-page":"00190","article-title":"Eradication of early MRSA infection in cystic fibrosis: a novel study design for the STAR-ter trial","volume":"8","author":"Cunningham","year":"2022","unstructured":"Cunningham F, Caldwell E, Mayer-Hamblett N, et al. Eradication of early MRSA infection in cystic fibrosis: a novel study design for the STAR-ter trial. ERJ Open Res. 2022;8(4):00190\u201302022."},{"issue":"4","key":"i2331-348X-30-5-601-b17","series-title":"Thorax","first-page":"297","article-title":"Treatment decisions for MRSA in patients with cystic fibrosis (CF): when is enough, enough?","volume":"72","author":"Bell","year":"2017","unstructured":"Bell SC, Flume PA. Treatment decisions for MRSA in patients with cystic fibrosis (CF): when is enough, enough? Thorax. 2017;72(4):297\u2013299."},{"issue":"5","key":"i2331-348X-30-5-601-b18","series-title":"Pediatr Pulmonol","first-page":"1569","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor on bacterial cultures from people with cystic fibrosis","volume":"58","author":"Beck","year":"2023","unstructured":"Beck MR, Hornick DB, Pena TA, Singh SB, Wright BA. Impact of elexacaftor\/tezacaftor\/ivacaftor on bacterial cultures from people with cystic fibrosis. Pediatr Pulmonol. 2023;58(5):1569\u20131573."},{"issue":"3","key":"i2331-348X-30-5-601-b19","series-title":"Pediatr Pulmonol","first-page":"825","article-title":"Impact of elexacaftor-tezacaftor-ivacaftor on bacterial colonization and inflammatory responses in cystic fibrosis","volume":"58","author":"Sheikh","year":"2023","unstructured":"Sheikh S, Britt RD, Jr., Ryan-Wenger NA, et al. Impact of elexacaftor-tezacaftor-ivacaftor on bacterial colonization and inflammatory responses in cystic fibrosis. Pediatr Pulmonol. 2023;58(3):825\u2013833."}],"container-title":["The Journal of Pediatric Pharmacology and Therapeutics"],"original-title":[],"link":[{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/30\/5\/article-p601.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/30\/5\/article-p601.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/30\/5\/article-p601.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T22:03:40Z","timestamp":1763762620000},"score":1,"resource":{"primary":{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/30\/5\/article-p601.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":19,"journal-issue":{"issue":"5"},"URL":"https:\/\/doi.org\/10.5863\/jppt-24-00079","relation":{},"ISSN":["2331-348X","1551-6776"],"issn-type":[{"value":"2331-348X","type":"electronic"},{"value":"1551-6776","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]}}}